Objective-Our recent studies have highlighted membrane type-1 matrix metalloproteinase (MMP)-14 as a selective marker for an invasive subset of macrophages potentially related to atherosclerotic plaque progression. Moreover, colony stimulating factors (CSF) may exert divergent effects on macrophage MMP expression, possibly through microRNAs. We, therefore, aim to identify and test the pathophysiological role of microRNAs, which modulate macrophage MMP-14 expression in atherosclerotic plaque progression. Approach and Results-Compared with macrophage CSF-differentiated macrophages, granulocyte/macrophage CSFmatured macrophages exhibited reduced MMP-14 mRNA levels but increased protein expression and activity, which resulted in heightened macrophage invasion. MicroRNA-24, identified to target MMP-14, was accordingly increased in macrophage CSF compared with granulocyte/macrophage CSF macrophages. Silencing microRNA-24 in macrophage CSF macrophages significantly increased MMP-14 expression and enhanced their invasive capacity, mimicking granulocyte/macrophage CSF macrophages, and suggesting that granulocyte/macrophage CSF modulates MMP-14 protein expression and subsequent macrophage invasion in a microRNA-24-dependent manner. In human coronary atherosclerotic plaques, increased MMP-14 protein expression in foam cell macrophages was associated with lesions exhibiting histological characteristics associated with an unstable phenotype. Furthermore, microRNA-24 expression in these atherosclerotic plaques was inversely related to MMP-14 protein expression. Moreover, stable plaques contained higher microRNA-24 levels than unstable plaques, and microRNA-24 colocalized with foam cell macrophages that exhibited low MMP-14 protein expression. Finally, in atherosclerotic mice (apolipoprotein E-deficient), microRNA-24 inhibition increased plaque size and macrophage MMP-14 expression. Conclusions-Taken together, our data demonstrates that downregulation of microRNA-24 promotes an invasive macrophage subset and plays a novel regulatory role in MMP-14 proteolytic activity and, therefore, plaque stability, highlighting its therapeutic potential. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A therosclerotic plaque progression culminating in plaque rupture underlies the majority of cardiovascular related deaths. 1 Histopathologic studies of human atherosclerotic lesions have revealed that plaque progression and rupture are characterized by macrophage infiltration, lipid/necrotic core expansion, reduction in smooth muscle cell number, and decreased collagen content. 1, 2 The aforementioned characteristics are thought in part to be modulated by matrix metalloproteinases (MMPs), a large family of proteases capable of degrading both matrix and nonmatrix molecules found within atherosclerotic lesions. 3 Moreover, macrophagespecific MMP production and associated activity, have been proposed to drive the transition of stable atherosclerotic lesions with thick fibrous caps to rupture-prone lesions, 4 commonly referred to as thin cap fibro-atheroma. 2 harbors the ability to cause pericellular degradation because of its synthesis and membrane location in an active form. 5 MMP-14 is expressed by macrophages and foam cell macrophages in atherosclerotic plaques, 6 has been implicated in acute myocardial infarction, 7 and bone marrow-derived cell expression of MMP-14 can influence collagen content of mouse plaques, 8 implying an important role for MMP-14 in plaque stability.
Colony stimulating factors (CSF) support bone marrowderived monocyte-to-macrophage differentiation and additionally modulate macrophage phenotypes 9 and thus play direct roles in regulating inflammatory and immune responses. 10 Moreover CSFs are found within atherosclerotic lesions and accordingly harbor the potential to moderate all stages of atherosclerosis through overlapping and competitive effects. 11 MicroRNAs are a large group of short noncoding RNAs that can regulate protein expression through degradation of targeted mRNA or by blocking protein translation. With regards to cardiovascular disease, recent studies have demonstrated that specific microRNAs can control arterial remodeling, angiogenesis, and cardiac function. 12 However, the contribution of microRNAs in atherosclerotic plaque progression and in particular plaque macrophage behavior is less well known. Here, we show that microRNA-24 acts as an important regulator of macrophage invasion and apoptosis via a novel regulatory role in MMP-14 proteolytic activity. Hence, our findings intimate that microRNA-24 and MMP-14 represent suitable targets for therapeutic intervention in the setting of atherosclerosis-associated cardiovascular disease.
Methods
Materials and Methods are available in the online-only Supplement.
Results

Monocyte-to-Macrophage Differentiation Modulates MMP-14 Expression
Quantitative polymerase chain reaction revealed that MMP-14 mRNA expression is significantly increased after macrophage CSF (M-CSF) mouse monocyte-derived macrophage maturation for 7 days ( Figure 1A) . Conversely, MMP-14 protein expression was significantly reduced after M-CSF macrophage differentiation (compared with monocytes, as assessed by Western blotting [ Figure 1B ] and immunohistochemistry [ Figure IA in the online-only Data Supplement]). Time-course analysis revealed that MMP-14 mRNA expression was upregulated by day 6 (9-fold compared with day 0; P=0.05). In contrast, total MMP-14 protein expression was downregulated by day 4 ( Figure 1C ), notably active MMP-14 levels showed more pronounced effects and were significantly reduced by day 2 ( Figure 1C ). These findings suggest a post-transcriptional regulation of MMP-14 protein expression and, therefore, activity during M-CSF directed monocyte-to-macrophage differentiation. In contrast to M-CSF matured macrophages, granulocyte/ macrophage CSF (GM-CSF) differentiation reduced MMP-14 mRNA expression 2-fold ( Figure 1D ), whereas protein levels were significantly increased, as assessed by Western blotting ( Figure 1E ) and immunohistochemistry ( Figure IB in the online-only Data Supplement). Moreover, unlike M-CSF matured macrophages, a decrease in either MMP-14 mRNA or protein expression was not observed between monocytes and GM-CSF-differentiated macrophages ( Figure II in the onlineonly Data Supplement). Expectedly, STAT5 (signal transducer and activator of transcription 5) phosphorylation was significantly induced by GM-CSF macrophage differentiation compared with M-CSF ( Figure IIIA in the online-only Data Supplement), demonstrating canonical GM-CSF-directed downstream signaling. Furthermore, expression of the proconvertase furin, which activates intracellular MMP-14 before its translocation to the cell membrane, was increased in GM-CSFdifferentiated macrophages compared with M-CSF matured cells ( Figure IIIB in the online-only Data Supplement). Accordingly, GM-CSF-differentiated macrophages harbor a greater ability to express active MMP-14 on their cell membranes and thus facilitate invasion. Using a transwell invasion assay, GM-CSF-differentiated macrophages demonstrated increased invasion compared with M-CSF matured cells ( Figure 1F ). The invasive capability of GM-CSF-differentiated macrophages was significantly reduced by coincubation with an MMP-14-blocking antibody ( Figure 1F ), suggesting that heightened invasion is MMP-14 dependent.
In addition, we observed that GM-CSF-differentiated macrophages exhibited reduced proliferative rates as assessed by Western blotting for proliferating cell nuclear antigen expression ( Figure IVA 
MicroRNA-24 Regulates Macrophage MMP-14 Expression
The disparity in basal MMP-14 mRNA and protein expression between M-CSF and GM-CSF-differentiated macrophages suggests the involvement of a post-transcriptional mechanism such as microRNA regulation. Using an online database designed to identify putative microRNAs able to target specific 3ʹ-untranslated region (UTRs) (www.targetscan.org), we highlighted 3 mature microRNA sequences that potentially bind both mouse and human MMP-14 mRNA at the 3ʹ-UTR region, microRNA-24, microRNA-26a, and microRNA-181b ( Figure VI in the online-only Data Supplement). Compared with monocytes, only microRNA-24 was significantly upregulated ( Figure 2A ) after M-CSF induced mouse macrophage differentiation. Interestingly, a significant downregulation was observed for microRNA-181-b (Figure 2A ), whereas no significant change was determined for microRNA-26 ( Figure 2A ). These data suggest a role for microRNA-24 in downregulation of MMP-14 protein expression. In accordance with this hypothesis, microRNA-24 expression was significantly reduced ( Figure VIIA in the online-only Data Supplement) in GM-CSF differentiated mouse macrophages in comparison with M-CSF matured cells. Importantly, a similar downregulation in microRNA-24 expression (P<0.01) was observed in human GM-CSF matured macrophages compared with M-CSF-differentiated macrophages, demonstrating that the change in microRNA-24 expression during macrophage differentiation is not species specific. To confirm that microRNA-24 can directly target MMP-14 mRNA, we cloned the wild-type MMP-14-3ʹ-UTR and a mutated MMP-14-3ʹ-UTR lacking microRNA-24 putative binding sites into the firefly luciferase-containing expression vector pCpG-mcs. The normalized luciferase activity was consistently increased (P<0.05; Figure 
MicroRNA-24 Depletion in M-CSF-Macrophages Increases MMP-14 Protein/Activity and Invasion
In line with our hypothesis, addition of a microRNA-24 antagonist to 6-day M-CSF-differentiated macrophages had no effect on MMP-14 mRNA levels ( Figure IX in the online-only Data Supplement) but significantly elevated and restored MMP-14 protein expression compared with controls, as shown by Western blotting ( Figure 2B ) and verified by immunocytochemistry, demonstrating a 12.5-fold increase in the percentage of MMP-14 positive cells to 50±5% from 4±2% in controls ( Figure 2C ). As expected, no effect was observed after 2 days differentiation when MMP-14 protein expression has not yet decreased ( Figure 2B ). These data suggest strongly an involvement of microRNA-24 in modulating mouse macrophage MMP-14 protein expression/activity and potentially their invasive capability. Compared with controls cells, microRNA-24 silenced M-CSF macrophages demonstrated a 2.5-fold increase in gelatinolytic activity ( Figure  X in the online-only Data Supplement), which could be Functionally, silencing microRNA-24 resulted in a 5.1-fold increase in macrophage invasion compared with si-scrambled controls ( Figure 2D ), which was reversed in the presence of a MMP-14 neutralizing antibody ( Figure 2D ). Conversely, Western blotting demonstrated that overexpression of microRNA-24 significantly reduced MMP-14 protein levels in GM-CSF macrophages by 25±11% compared with scrambled microRNA control cells (P<0.05; Figure VIIB in the onlineonly Data Supplement). Hence, microRNA-24 seems to act as an important modulator of MMP-14 expression and activity in macrophages affecting their invasive capability. Moreover, our findings also suggest an important role played by CSFs in microRNA-24 modulation, which can result in the regulation of several biological processes.
Neither GM-CSF Macrophage Differentiation Nor MicroRNA-24 Modulation Is Associated With M1 or M2 Macrophage Polarization
Recent evidence has intimated that in vitro identified macrophage heterogeneity can be classified primarily as M1 proinflammatory macrophages and M2 anti-inflammatory macrophage subsets. 4 Accordingly, we evaluated whether well-classified gene products associated with M1 or M2 macrophage polarization aligned with either M-CSF-or GM-CSF-differentiated macrophages. Although the M2 markers interleukin-10 and CD163 mRNA expression were significantly reduced in GM-CSF macrophages, MRC1 (macrophage mannose receptor 1) was significantly increased (P<0.05; Figure 3A ) compared with M-CSF-differentiated macrophages. Moreover no differences in 6 other selected genes were detected ( Figure 3A ). In addition, although increased macrophage MMP-14 mRNA expression was associated with M1 polarization in M-CSF-and GM-CSF-differentiated macrophages ( Figure XIA in the online-only Data Supplement), no such relationship was observed for MMP-14 protein expression or microRNA-24 levels, which were solely GM-CSF responsive ( Figure XIB and XIC in the online-only Data Supplement). Consequently, silencing microRNA-24 expression in M-CSF-or GM-CSF-differentiated macrophages was not allied with a gene expression pattern characteristic of either M1 or M2 macrophage subsets ( Figure 3B and 3C ). Finally, variances in differentiation/maturation rates between M-CSF and GM-CSF monocyte/macrophages may in part account for our observed changes in microRNA-24 levels and MMP-14 protein expression; however, we did not detect any differences in the expression of the macrophage maturation markers CD36 or macrophage scavenger receptor-1 during M-CSF or GM-CSF macrophage differentiation ( Figure 3D and 3E).
MicroRNA-24 Regulates In Vivo Macrophage MMP-14 Protein/Activity and Invasion
To corroborate our findings in vivo, we have used a mouse model of granuloma formation using matrigel-infused subcutaneous polyurethane sponges. First, using magnetic bead separation, we demonstrate that foam cell macrophages isolated from in vivo sponges exist as both MMP-14 positive and 
MicroRNA-24 Inhibition and Increased MMP-14 Macrophage Expression Is Associated With Plaque Progression
Subsequently, to test our hypothesis that loss of microRNA-24 expression and concomitant increased MMP-14 protein expression/activity promotes atherosclerotic plaque progression, mice with preexisting atherosclerotic lesions within their brachiocephalic arteries were treated with a locked nucleic acid -modified microRNA-24 inhibitor or a scrambled microRNA to serve as a control (n=6 per group). As expected, microRNA-24 inhibition resulted in a significant increase in intraplaque MMP-14 positive macrophages (2.2-fold; P<0.05; Figure 4A ). Accordingly, MMP-14-dependent proteolytic activity within plaques was augmented compared controls (1.9-fold; P<0.05; Figure 4B ), as ascertained by in situ zymography with and without a MMP-14 neutralizing antibody. This translated to an acceleration in plaque progression as observed by an increase in lesion area of microRNA-24 inhibitor-treated mice versus controls (2.1-fold; P<0.05; Figure 5A ). Compared with baseline lesions at the point of intervention, microRNA-24 inhibitor treatment increased lesion area 3.2-fold (P<0.05; Figure 5A ), substantiating the dramatic acceleration in plaque progression of microRNA-24 inhibitor-treated mice. In addition, pathological characteristics associated with a more unstable plaque phenotype were altered in treated mice compared with control animals: smooth muscle cell to macrophage ratio (64% decrease; P<0.05; Figure 5B ), collagen content (39% decrease; P<0.05; Figure  XIVA in the online-only Data Supplement), and lipid core size (50% increase; P<0.05; Figure XIVB in the online-only Data Supplement). The observed effects on SMC to macrophage ratio were principally because of a 2.1-fold increased plaque macrophage content (P<0.05; Figure 5B ) in microRNA-24 inhibitor-treated mice, although a nonsignificant 30% reduction in vascular smooth muscle cell number was also observed ( Figure 5B ). Moreover and in line with our in vitro data, intraplaque macrophage proliferation rates were reduced (34%;
P<0.05; Figure XVA in the online-only Data Supplement), whereas apoptotic frequencies were increased (39%; P<0.05; Figure XVB in the online-only Data Supplement) in brachiocephalic plaques from microRNA-24 inhibitor-treated mice compared with scrambled control animals. These results suggest that loss of microRNA-24 dramatically increases macrophage MMP-14 expression/activity and thus drives plaque progression toward an advanced/unstable phenotype.
In an attempt to elucidate the mechanisms regulating the observed differences in macrophage proliferation, particularly given the recent evidence that macrophage proliferation may play a more critical role in atherosclerosis than previously considered, 13 we investigated the expression of the cyclin-dependent kinase inhibitors p16 and p27, which have been shown to be regulated by microRNA-24. 14 In partial agreement with a recent study, 13 Body weights were comparable between scrambled control (29.7±1.1 g) and microRNA-24 inhibitor-treated mice (28.2±1.5 g), indicating that locked nucleic acid-microRNA treatment was well tolerated, and no significant effect on lipid profiles was observed ( Figure XVII in the online-only Data Supplement). High-fat feeding is known to induce monocytosis, 15 and it is plausible that the proatherosclerotic effects observed in microRNA-24 inhibitor-treated mice may be because of increased circulating monocyte numbers; however, no differences were detected ( Figure XVIII in the online-only Data Supplement).
MicroRNA-24 Expression Is Attenuated in Unstable Human Coronary Atherosclerotic Plaques
To validate our findings in human atherosclerosis, we observed an increased number of MMP-14 positive foam cell macrophages in human coronary artery atherosclerotic plaques characterized as unstable (3.5-fold; P<0.05; Figure 6 ) compared with stable lesions. Furthermore, microRNA-24 expression in atherosclerotic plaques is inversely related with MMP-14 protein expression because stable plaques contained higher microRNA-24 levels (as assessed by quantitative polymerase chain reaction) than unstable plaques (2-fold; P<0.05; Figure 6 ). Moreover, in situ hybridization revealed that the proportion of foam cell macrophages expressing microRNA-24 was significantly higher in stable plaques compared with unstable plaques (1.9-fold; P<0.05; Figure 6 ) in direct contrast to MMP-14 protein expression. In addition, although the percentage of intraplaque macrophages expressing M-CSF was decreased in unstable human coronary atherosclerotic plaques (51%; P<0.05; Figure XIXA -XIXC in the online-only Data Supplement), GM-CSF positive macrophage number was significantly increased in unstable plaques compared with stable lesions (70%; P<0.05; Figure XIXA -XIXC in the online-only Data Supplement). Finally, we observed a high level of correlation between the number of MMP-14and GM-CSF-positive macrophages in advanced plaques (r 2 =0.606; P<0.0002; Figure XIXD in the online-only Data Supplement).
Discussion
The interminable recruitment of inflammatory monocyte/ macrophages and their associated increased proteolytic potential are considered pivotal to atherosclerotic lesion progression and rupture. In our current study, we demonstrate that perturbation of macrophage microRNA-24 heightens their proteolytic capacity and renders them proatherosclerotic. During M-CSF directed macrophage maturation, expression of microRNA-24 is essential for the downregulation of MMP-14 protein expression. However, GM-CSF matured macrophages exhibit retarded microRNA-24 levels, resulting in elevated MMP-14 activity and promoting a proinflammatory phenotype characterized as invasive and proapoptotic, but with reduced proliferative rates. Consequently, in vivo microRNA-24 inhibition augmented the progression of established atherosclerotic plaques associated with increased expression and activity of MMP-14 in intraplaque macrophages. In addition, plaque composition was altered and exhibited characteristics associated with unstable plaques in man. Furthermore, reduced microRNA-24 expression occurred in human plaques histologically characterized as unstable and correlated with increased macrophage MMP-14 expression. Therefore, GM-CSF sensitized macrophages display increased MMP-14-dependent proteolytic potential through suppression of microRNA-24 and drive advanced atherosclerotic plaque progression. per group; data expressed as mean±SEM). Scale bar in i represents 100 μm and is applicable to both panels. B, Quantification of gelatinolytic activity as assessed by in situ zymography of brachiocephalic artery atherosclerotic lesions from control and miR-24 inhibitor-treated mice, incubated with substrate alone (i and ii) or plus 15 ng/mL MMP-14 blocking antibody (BAb; iii and iv). Green fluorescence represents gelatinolytic activity (*P<0.05 and denotes significant difference from scrambled controltreated mice; #P<0.05 and represents significant difference from substrate alone; n=6 per group; data expressed as mean±SEM). Scale bar in i represents 100 μm and is applicable to i-iv.
MMPs and TIMPs (tissue inhibitors of metalloproteinases) play a complex and diverse roles during the pathogenesis of atherosclerosis and plaque instability. 3 These varied functions include matrix degradation but also regulation of the proliferation, migration, and apoptosis of monocyte/macrophages 4 and vascular smooth muscle cells. 16 Consequently, in vitro and in vivo studies have demonstrated that distinct MMPs are used by individual cell types to modulate their behavior. Accordingly some MMPs clearly promote plaque growth and development of vulnerable morphologies in experimental models while others do not. 17 MMP-14 has been proposed as a proatherosclerotic protease because of its abundant expression by macrophages within human atherosclerotic plaques 6, 18 and that proinflammatory molecules such as tumor necrosis factor-α and oxidized low-density lipoprotein upregulate macrophage MMP-14 expression. 6, 18 Moreover, several studies have demonstrated that MMP-14 plays a fundamental role in permitting monocyte/ macrophage invasion [19] [20] [21] [22] and may promote further inflammatory/immune cell recruitment through elevation of proinflammatory cytokine and chemokine release. 22 Consequently, it was illustrated that MMP-14 deficiency in bone marrow-derived cells (primarily macrophages) retards collagen loss from murine atherosclerotic lesions, thus favorably altering the biomechanical properties of the plaque toward a more stable phenotype. 8 Recent findings including our own have highlighted that MMP-14 expression predominates in foam cell macrophages, which are associated with plaque progression. 18, 23, 24 Moreover, elevated MMP-14 protein expression in foam cell macrophages affords them greater invasive capacity, increased proteolytic potential, and heightened susceptibility to apoptosis, properties expected to increase plaque advancement and instability. 23 Our present results demonstrate that increased MMP-14 protein expression through microRNA-24 inhibition accelerated atherosclerosis, which was associated with increased macrophage accumulation, intraplaque MMP-14-dependent activity, and heightened rates of apoptosis, mirroring our previous in vitro studies. Validative studies in human coronary plaques demonstrated that foam cell macrophage expression was increased in advanced unstable lesions, alongside a decrease in microRNA-24. Importantly, the number of foam A, Quantification of plaque cross-sectional area in picro-sirius red-stained brachiocephalic artery atherosclerotic lesions from 12 week baseline, control, and miR-24 inhibitor-treated mice (*P<0.05 denotes significant difference from baseline; #P<0.05 represents significant difference from control and baseline; n=6 per group; data expressed as mean±SEM). Scale bar in i represents 100 μm and is applicable to i-iii. B, Total numbers of lesional smooth muscle cells (SMC) and macrophages were counted and the ratio computed as summarized in the adjoining graph (*P<0.05; n=6 per group; data expressed as mean±SEM). Graphs for macrophage and smooth muscle cell content are also depicted separately (*P<0.05). Scale bar in i represents 100 μm and is applicable to i-iv.
cell macrophages expressing MMP-14 was altered between plaque phenotypes and was inversely related to microRNA-24 expression, suggesting a role of divergent foam cell macrophage populations with regard to MMP-14 activity. In agreement, we previously identified that increased MMP-14 protein expression and activity was apparent in only a subpopulation of foam cell macrophages, 23 intimating that our observed changes may be because of disparate macrophage phenotypes. Intriguingly, it has been recently postulated that intraplaque macrophage proliferation predominates over monocyte influx in murine atherosclerosis. 13 Conversely, our data implies that in advanced lesions within the brachiocephalic arteries of apoE knockout mice, modulation of monocyte/macrophage migration/invasion plays a more prominent role in plaque progression of existing lesions and that macrophage proliferation seems less prominent and limited to protective macrophage subsets and may, therefore, be beneficial for plaque stability.
There has been recent interest within the cardiovascular research field in delineating and extrapolating the atherosclerotic effects of pro-and anti-inflammatory macrophages, in particular classically (termed M1) and alternatively activated (M2) macrophages. 4, 25 Moreover, a myriad of differing macrophage subsets have now been revealed and identified within atherosclerotic plaques. 26 The CSFs GM-CSF and M-CSF have also been shown to polarize macrophages divergently into 2 distinct macrophage subsets 9, 27 and postulated to foster M1 and M2 macrophages, respectively. However, in vitro classified M1 and M2 macrophage subsets do not substantially represent or overlap with M-CSF-or GM-CSF-differentiated macrophages. 11 Accordingly in this study, MMP-14 mRNA expression was lower in GM-CSF macrophages compared with M-CSF matured macrophages, whereas levels are heightened in M1 macrophages related to nonpolarized macrophages. 28 Furthermore, MMP-14 protein expression follows mRNA levels in M1 macrophages 28 while we demonstrate that GM-CSF macrophages post-transcriptionally modulate MMP-14 protein expression through downregulation of microRNA-24. Furthermore, microRNA-24 expression is not altered among monocyte-derived macrophages driven toward either a M1 or M2 phenotype, 29 indicating that GM-CSF macrophages do not represent M1 macrophages. In agreement, our own findings demonstrate that M-CSF and GM-CSF polarized macrophage populations show no consistent or clear overlap with M1 or M2 macrophage subsets, indicating that they do not represent classically or alternatively activated macrophages as so defined. Moreover, as recently shown by de Winther and colleagues, 30 the macrophages in human plaques do not accurately conform to the M1/M2 paradigm, and we think the MMP-14 positive subpopulation detected in plaques does not clearly represent any of these in vitro-defined subsets.
An association between microRNAs and macrophage polarization has recently been highlighted, 31 indicating that a small number of microRNAs foster the potential to regulate macrophage plasticity. Conversely, a limited number of microRNAs are differentially expressed in divergently polarized macrophages, 29 implying that the spectrum of activation states observed in differentially polarized macrophages may in part be under microRNA-dependent regulation. Our current findings fit with this hypothesis, revealing that the proatherosclerotic effects associated with GM-CSF-dependent MMP-14 expressing macrophages are to some extent regulated by microRNA-24 levels. Supportingly, Nazari-Jahantigh et al 32 recently demonstrated that microRNA-24 levels are reduced in inflammatory macrophages and importantly within murine atherosclerosis plaques. 32 Moreover, recent evidence has demonstrated that M-CSF can regulate monocyte/macrophage microRNA expression. 33 Conversely, macrophage expression of MMP-14 18 and GM-CSF 34 is prevalent in advanced human atherosclerotic plaques. Our own findings demonstrate and corroborate that macrophage GM-CSF expression is heightened and surmounts M-CSF expression in advanced unstable human atherosclerotic plaques and may, therefore, potentiate a GM-CSF dominant microenvironment. While in murine studies, bone marrow-specific loss of MMP-14 8 or global GM-CSF deficiency 35 attenuates atherosclerotic plaque development. Collectively, the published literature and our findings support modulating microRNA-24 expression or MMP-14 activity as therapeutic strategies for atherosclerosis. In addition, a multitude of studies have established the potential of retarding murine plaque progression through modulating microRNA expression, 32, [36] [37] [38] [39] adding credence to our own proof-of-principle experiments, which reveal the potential of reversing plaque progression. Interestingly, a recent phase II clinical trial has demonstrated the feasibility of locked nucleic acid-modified inhibitors to target specific microRNA in human disease. 40 We are aware that microRNA-24 has many additional predicted targets which may be involved in the antiatherosclerotic action of M-CSF-differentiated macrophages, especially in vivo where target availability may change. However, our target modulation experiments both in vitro and in vivo demonstrated a dominant role of MMP-14 in the proapoptotic and proinvasive effects subsequent to microRNA-24 inhibition. In particular, the striking regulation of MMP-14 protein expression in vitro and particularly in vivo macrophages, within subcutaneous sponges and atherosclerotic plaques, supports MMP-14 as a prominent target of microRNA-24. The role of other potential targets of microRNA-24 on the observed pathophysiological effect remains to be elucidated. We have not clarified the mechanism underlying the small but significant difference in MMP-14 mRNA expression between M-CSF and GM-CSF polarized macrophages because of the enormity of this task. It is possible the stability of the mRNA coding for MMP-14 rather than differences in promoter activation underlie the observed differences. There is supporting evidence that target mRNA bound to its microRNA prevents immediate exosome complex-mediated degradation (with consequential reduction in mRNA levels) and are instead retained and accumulate within P-bodies and, therefore, can result in an increase in mRNA levels when detected by quantitative polymerase chain reaction. 41 In summary, through a series of in vitro and in vivo functional and mechanistic studies, we show that downregulation of microRNA-24 promotes an invasive macrophage subset and plays a novel regulatory role in MMP-14 proteolytic activity, promoting atherosclerotic plaque progression and characteristics associated with plaque vulnerability. Hence, we conclude that CSF regulation of microRNA-24 plays a strategic role in the proatherosclerotic programming of macrophages, highlighting its therapeutic potential.
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